Wall Street Zen Upgrades Senti Biosciences (NASDAQ:SNTI) to Hold

Senti Biosciences (NASDAQ:SNTI) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a report released on Saturday.

A number of other research analysts have also weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Thursday, January 22nd. Chardan Capital boosted their target price on Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Senti Biosciences Stock Performance

Shares of NASDAQ:SNTI opened at $0.79 on Friday. The firm has a market cap of $20.77 million, a price-to-earnings ratio of -0.25 and a beta of 2.12. The firm has a fifty day moving average price of $0.95 and a 200 day moving average price of $1.38. Senti Biosciences has a fifty-two week low of $0.79 and a fifty-two week high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.10). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $1.00 million. As a group, research analysts predict that Senti Biosciences will post -14.54 earnings per share for the current year.

Hedge Funds Weigh In On Senti Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Armistice Capital LLC purchased a new position in shares of Senti Biosciences in the 2nd quarter worth $1,883,000. Geode Capital Management LLC raised its position in shares of Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after buying an additional 117,588 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Senti Biosciences in the 3rd quarter valued at about $117,000. Virtu Financial LLC bought a new position in shares of Senti Biosciences in the 4th quarter valued at about $46,000. Finally, Jane Street Group LLC purchased a new position in Senti Biosciences in the fourth quarter worth about $40,000. 25.70% of the stock is owned by hedge funds and other institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.